 IRVINE, Calif., Sept. 06, 2022 GLOBE NEWSWIRE -- Reneo Pharmaceuticals, Inc. NASDAQ: RPHM, a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the companys management team will participate at the following conferences in September, as detailed below: 